The Latest Cardiac and Vascular News
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019. AtriCure will host […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and related conditions, today announced fourth quarter and full year 2018 financial results. “We are pleased with our fourth quarter performance, capping a year of strong, […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE® cryoSPHERE™ probe in the United States. The cryoSPHERE probe is the first device […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2018 and provided 2019 financial guidance. Preliminary, […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 30thAnnual Healthcare Conference in New York City on Wednesday, […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2018 financial results. “We are pleased with our third quarter performance and building track record of […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences. AtriCure is scheduled to present at the […]
